Join to View Full Profile
195 Little Albany StreetNew Brunswick, NJ 08903
Phone+1 732-235-2465
Dr. Packiam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Vignesh Packiam, MD received his medical degree from the University of Pittsburgh, followed by residency at the University of Chicago, and a two-year Society of Urologic Oncology accredited fellowship at Mayo Clinic. Dr. Packiam treats genitourinary malignancies including bladder, prostate, kidney, and testicular cancer, and is experienced in open and robotic surgery. He has a background in clinical trials and feels it is important to educate his patients about all available options. He has a clinical interest in bladder cancer and supports patient centered groups such as the Bladder Cancer Advocacy Network. He is an active member of numerous cancer societies, serves as a reviewer for multiple urology journals, and has authored over 100 peer-reviewed articles and book chapters.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Minimally Invasive Urologic Surgery, 2018 - 2020
University of ChicagoResidency, Urology, 2012 - 2018
University of Pittsburgh School of MedicineClass of 2012
University of Wisconsin-MadisonB.S., Biology, Philosophy, Dean's Scholar, 2004 - 2008
Certifications & Licensure
IA State Medical License 2020 - 2025
NJ State Medical License 2023 - 2025
MN State Medical License 2018 - 2021
WI State Medical License 2018 - 2021
IL State Medical License 2015 - 2020
American Board of Urology Urology
Publications & Presentations
PubMed
- Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?Ian M McElree, Grant M Henning, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott
BJU International. 2025-07-01 - Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer.Ian M McElree, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Vignesh T Packiam
European Urology Focus. 2025-06-26 - Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Compar...Sam S Chang, Bryn Launer, Vikram Narayan, Dattatraya Patil, Michael A O'Donnell
European Urology. 2025-06-12
Press Mentions
ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)June 10th, 2025- Gemcitabine-Docetaxel Effective Alternative to BCG in NMIBCMarch 7th, 2023
- Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients with Non–Muscle-Invasive Bladder Cancer Amid BCG ShortageMarch 1st, 2023
- Join now to see all
External Links
- Websitehttps://www.cinj.org/vignesh-t-packiam-md
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
